ReviewClinical liver disease2021
The Multidisciplinary Management of Hepatocellular Carcinoma.
Review in Clinical liver disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Novel Silver(I) and Gold(I) N-Heterocyclic Carbene Complexes Induce ROS-Dependent Autophagic Cell Death in Human Hepatoma Cell Line HepG2.Chemical biology & drug design · 2026Article
- Multidisciplinary Clinic Approach Improves Immunotherapy Treatment Outcomes in Unresectable Hepatocellular Carcinoma: A Multicentre Retrospective Study.Liver cancer · 2026Article
- Optimizing Liver Cancer Care Through BCLC Principles.Seminars in liver disease · 2026Review
- Diagnosis, clinical assessment, and staging of hepatocellular carcinoma: a Brazilian multidisciplinary consensus.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2026Article
- Management of Advanced Hepatocellular Carcinoma: A Review and Practical Guide.JCO oncology practice · 2025Review
- Multidisciplinary approach for hepatocellular carcinoma patients: current evidence and future perspectives.Journal of liver cancer · 2024Article
- Scoping review of values elicitation tools for treatment decisions in hepatocellular carcinoma.BMC gastroenterology · 2024Article
- Hepatocellular Carcinoma from a Hepatologist's Perspective.Seminars in interventional radiology · 2023Review
- Possible Use of miR-223-3p as a Prognostic Marker in Transarterial Chemoembolization Treatment of Hepatocellular Carcinoma Patients.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Is multidisciplinary treatment effective for hepatocellular carcinoma with portal vein tumor thrombus?Journal of liver cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.